Analysts Offer Insights on Healthcare Companies: Bio-Rad Laboratories (BIO) and Ramsay Health Care (OtherRMSYF)
Confident Investing Starts Here:
Bio-Rad Laboratories (BIO)
RBC Capital analyst Conor McNamara maintained a Buy rating on Bio-Rad Laboratories on June 5 and set a price target of $381.00. The company's shares closed last Monday at $225.56.
According to TipRanks.com, McNamara 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -22.5% and a 18.4% success rate. McNamara covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, SOPHiA GENETICS, and Exact Sciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bio-Rad Laboratories with a $316.40 average price target.
In a report released today, Steven Wheen from Jarden maintained a Hold rating on Ramsay Health Care, with a price target of A$44.05. The company's shares closed last Thursday at $24.00.
According to TipRanks.com, Wheen is ranked #1103 out of 9627 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Ramsay Health Care with a $25.09 average price target.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Trump doubles down on Most Favored Nation plan to target drug prices
US President Donald Trump has called on pharmaceutical manufacturers to lower US drug prices in line with the Most Favored Nation (MFN) policy first proposed in an executive order in May. On 31 July, the White House said letters were sent to leading pharmaceutical manufacturers like AstraZeneca, AbbVie, Eli Lilly, Regeneron, Novartis, Pfizer, and more, calling on them to take steps to lower drug prices in the US such that they match the lowest prices in other developed countries within the next 60 days. President Trump also shared many of these letters on the social media platform Truth Social. While this is not the first time the administration has floated the MFN policy, this time, the language used to address pharma companies is more aggressive. If the companies do not comply, the order states, the federal government 'will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices.' In response to this statement, a spokesperson for the industry body BIO said, 'We share the Administration's goal of ending foreign freeloading on American innovation. But importing socialist price controls would lead only to fewer new medicines and the rationing of healthcare for Americans and would strengthen and embolden foreign adversaries whose goal is to dominate the world in biotechnology.' The BIO spokesperson said eliminating the middlemen, ending the abuse of drug reimbursement programs like 340B would be a way to simplify the system, protect patients and narrow the pricing gap between the US and other developed countries. 'Middlemen' or pharmacy benefit managers (PBMs) are often blamed by the pharmaceutical companies for high drug prices. PBMs on their part have said they negotiate with different stakeholders to drive down costs, and pass on savings obtained through rebates and discounts to health plans. The letter to the manufacturers implores them to provide drug at 'MFN rates' to all Medicaid patients, and commit to providing these prices for newly launched drugs to all major US buyers like Medicare and commercial plans. The latest announcement also calls on drug manufacturers to opt in for platforms where drugs can be sold directly to patients at prices that are comparable to those in developed nations, which are currently offered to third party payers. Among the letters posted on Truth Social, Trump directly called on several CEOs like Albert Bourla of Pfizer, and Leonard Schleifer of Regeneron, by using their first names instead of a formal address. Several countries use international reference pricing as a strategy in their health systems. However, chief among the criticism following the May executive order has been the lack of details. Industry experts have highlighted a lack of clarity on how any potential list price changes will affect the prices patients pay at the pharmacy counter given the complex dynamics and multiple stakeholders in the US healthcare system. There is also a concern that if the US implements reference pricing, it could influence when companies choose to launch drugs in certain ex-US markets to avoid those potentially lower prices from being used as references. Furthermore, pharma companies have chosen the litigation route to fight legislative changes targeting drug prices, like the Inflation Reduction Act, and the same could be seen with the MFN executive order, as per a Bank of America report. "Trump doubles down on Most Favored Nation plan to target drug prices" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. 登入存取你的投資組合
Business Insider
19 hours ago
- Business Insider
Analysts Offer Insights on Real Estate Companies: Mapletree Commercial (OtherMPCMF) and Extra Space Storage (EXR)
Companies in the Real Estate sector have received a lot of coverage today as analysts weigh in on Mapletree Commercial (MPCMF – Research Report) and Extra Space Storage (EXR – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Mapletree Commercial (MPCMF) In a report released today, Geraldine Wong from DBS maintained a Buy rating on Mapletree Commercial, with a price target of S$1.50. The company's shares closed last Monday at $0.85. According to Wong is a 3-star analyst with an average return of 2.4% and a 60.5% success rate. Wong covers the NA sector, focusing on stocks such as CDL Hospitality Trusts, Mapletree Logistics, and Frasers Centrepoint. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Mapletree Commercial with a $1.17 average price target. Extra Space Storage (EXR) In a report released today, Juan C. Sanabria from BMO Capital maintained a Hold rating on Extra Space Storage, with a price target of $165.00. The company's shares closed last Wednesday at $149.34. According to Sanabria is a 2-star analyst with an average return of 0.2% and a 46.5% success rate. Sanabria covers the NA sector, focusing on stocks such as SmartStop Self Storage REIT, Inc., National Storage Affiliates, and National Health Investors. Extra Space Storage has an analyst consensus of Moderate Buy, with a price target consensus of $153.92, implying a 1.2% upside from current levels. In a report issued on July 23, Wells Fargo also maintained a Hold rating on the stock with a $160.00 price target.
Business Insider
20 hours ago
- Business Insider
Analysts Have Conflicting Sentiments on These Real Estate Companies: Ventas (VTR), Independence Realty (IRT) and Whitestone REIT (WSR)
Companies in the Real Estate sector have received a lot of coverage today as analysts weigh in on Ventas (VTR – Research Report), Independence Realty (IRT – Research Report) and Whitestone REIT (WSR – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Ventas (VTR) In a report released today, Juan C. Sanabria from BMO Capital maintained a Buy rating on Ventas, with a price target of $75.00. The company's shares closed last Wednesday at $66.48, close to its 52-week high of $71.04. According to Sanabria is a 2-star analyst with an average return of 0.2% and a 46.5% success rate. Sanabria covers the NA sector, focusing on stocks such as SmartStop Self Storage REIT, Inc., National Storage Affiliates, and National Health Investors. Currently, the analyst consensus on Ventas is a Strong Buy with an average price target of $73.78. Independence Realty (IRT) In a report released today, John Kim from BMO Capital maintained a Hold rating on Independence Realty, with a price target of $20.00. The company's shares closed last Wednesday at $17.13. According to Kim is a 1-star analyst with an average return of -0.2% and a 45.1% success rate. Kim covers the NA sector, focusing on stocks such as Easterly Government Properties, Hudson Pacific Properties, and Rexford Industrial Realty. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Independence Realty with a $22.00 average price target, implying a 26.0% upside from current levels. In a report issued on July 15, Barclays also maintained a Hold rating on the stock with a $22.00 price target. Whitestone REIT (WSR) Colliers Securities analyst Barry Oxford maintained a Buy rating on Whitestone REIT today and set a price target of $14.00. The company's shares closed last Wednesday at $12.39. According to Oxford is a 2-star analyst with an average return of 0.4% and a 49.8% success rate. Oxford covers the NA sector, focusing on stocks such as Bluerock Homes Trust, Inc. Class A, Alpine Income Property Trust Inc, and National Retail Properties. Whitestone REIT has an analyst consensus of Strong Buy, with a price target consensus of $15.25, representing a 19.9% upside. In a report issued on July 16, TR | OpenAI – 4o also upgraded the stock to Buy with a $13.50 price target.
